Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2725 - Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients.


30 Sep 2019


Poster Display session 3


Marina Bosch - Damas


Annals of Oncology (2019) 30 (suppl_5): v836-v845. 10.1093/annonc/mdz276


M. Bosch - Damas1, M. Rodriguez - Reyes2, M. Cervera - Carbonell1, N. Borràs - Maixenchs1, E. Carcelero - San Martín3, G. Riu - Viladoms2, M. Valverde - Bosch1, G. Gutierrez - Garcia1

Author affiliations

  • 1 Icmho, Hospital Clínic Barcelona, 08036 - Barcelona/ES
  • 2 Pharmacy, Hospital Clínic Barcelona, Barcelona/ES
  • 3 Pharmacy, Hospital Clínic Barcelona, 08036 - Barcelona/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2725


The oral, fixed-combination NEPA containing netupitant and palonosetron target crucial pathways involved in both acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients with highly emetogenic chemotherapy.Hematopoietic stem cell transplantation (HSCT) is associated with infectious complications, especially bloodstream infections (BSI). The risk factors associated with BSI include presence of indwelling vascular catheters. NEPA eliminates accessing intravenous catheters leading to a decreased risk of infection in HSCT recipients.There is a paucity of studies about the management of CINV during preparative regimens for HSCT. The aim of this study was to assess the safety of NEPA during and after HSCT conditioning.


Patients with chronic myeloid leukemia, multiple myeloma, myelodysplastic syndrome, and acute myeloid leukemia who received an allogeneic HSCT between 2017 and 2018 were retrospective studied. Conditioning regimen consisted of fludarabine and busulfan. Graft versus host disease prophylaxis was done with high-dose cyclophosphamide on days +3 to + 4 post-HSCT. Patients received a single capsule of NEPA prior to conditioning regimen and before cyclophosphamide, both with oral dexamethasone on days 1-3 . Safety was assessed by evaluation of adverse events and use of rescue medications (baclofen for hiccups and lactitol, macrogol and sennosides for constipation).


Six patients were included: 4/6were male and median age was 50 years (IQR: 46-53 years). Two patients reported hiccups needing baclofen and 6 required rescue medications for constipation. Five out of six patients presented neutropenic enterocolitis on day +7, oral intake was stopped in 4 of them, total parenteral nutrition was started in 3 cases, 3 patients required extra antibiotic coverage, and 4 received analgesic therapy. All patients improved with conservative measures.


In this real-world observational study, the incidence of neutropenic enterocolitis was considerably higher than previous reports in HSCT recipients. It may be associated with NEPA administration but future studies will be needed to confirm this relationship.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Hospital Clínic Barcelona.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.